Myth: Alternative nicotine products don't help people stop smoking: Difference between revisions
Jump to navigation
Jump to search
| Line 48: | Line 48: | ||
===2021: [https://pubmed.ncbi.nlm.nih.gov/34002223/ Differences in Switching Away From Smoking Among Adult Smokers Using JUUL Products in Regions With Different Maximum Nicotine Concentrations: North America and the United Kingdom]=== | ===2021: [https://pubmed.ncbi.nlm.nih.gov/34002223/ Differences in Switching Away From Smoking Among Adult Smokers Using JUUL Products in Regions With Different Maximum Nicotine Concentrations: North America and the United Kingdom]=== | ||
*In this longitudinal study of N.Am. and UK smokers who purchased JUUL, switch rates were higher in the N.Am. users, where smokers were using higher nicotine concentrations. The results were robust to multiple adjustments for differences between the two nicotine concentration policy regions across different statistical approaches, including PSM on relevant observable characteristics. These results have implications for regulatory policy, as the availability of ENDS with nicotine concentrations greater than 20 mg/mL may facilitate switching away from cigarette among adult smokers. | *In this longitudinal study of N.Am. and UK smokers who purchased JUUL, switch rates were higher in the N.Am. users, where smokers were using higher nicotine concentrations. The results were robust to multiple adjustments for differences between the two nicotine concentration policy regions across different statistical approaches, including PSM on relevant observable characteristics. These results have implications for regulatory policy, as the availability of ENDS with nicotine concentrations greater than 20 mg/mL may facilitate switching away from cigarette among adult smokers. | ||
===2021: [https://pubmed.ncbi.nlm.nih.gov/33894796/ Switching away from Cigarette Smoking with JUUL: Populations of Special Interest]=== | |||
*Substantial rates of complete switching were consistently achieved across all medico-socio-demographic subgroups 12 months following the purchase of the JSK. The potential benefits of switching with JUUL on smokers are likely to be experienced by a wide range of adult smokers. | |||
===2020: [https://pubmed.ncbi.nlm.nih.gov/32877429/ Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16]=== | ===2020: [https://pubmed.ncbi.nlm.nih.gov/32877429/ Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16]=== | ||